India – Generic breast cancer drug coming to India

Eribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.

Pune-based Emcure Pharma on Wednesday said it is launching the generic version of Eisai Pharma’s breast cancer medicine Eribulin, which will be 40% cheaper than the innovator’s.

Eribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial. It is one of the leading drugs in Eisai’s portfolio with a market size of Rs 50-60 crore.

Emcure said it is launching the generic version as Eisai’s product patent…